Warfarin

Generic Name
Warfarin
Brand Names
Coumadin, Jantoven
Drug Type
Small Molecule
Chemical Formula
C19H16O4
CAS Number
81-81-2
Unique Ingredient Identifier
5Q7ZVV76EI
Background

Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.

Indication

Indicated for:

1) Prophylaxis and treatment of venous thromboembolism and related pulmonary embolism.

2) Prophylaxis and treatment of thromboembolism associated with atrial fibrillation.

3) Prophylaxis and treatment of thromboembolism associated with cardiac valve replacement.

4) Use as adjunct therapy to reduce mortality, recurrent myocardial infarction, and thromboembolic events post myocardial infarction.

Off-label uses include:

1) Secondary prevention of stroke and transient ischemic attacks in patients with rheumatic mitral valve disease but without atrial fibrillation.

Associated Conditions
Myocardial Infarction, Pulmonary Embolism, Stroke, Systemic Embolism, Thromboembolism, Transient Ischemic Attack, Venous Thrombosis (Disorder)
Associated Therapies
-

Study to Compare Pharmacokinetics & Pharmacodynamics of Warfarin & Esmolol in the Absence & Presence of MEDI0382

First Posted Date
2017-11-20
Last Posted Date
2018-04-25
Lead Sponsor
MedImmune LLC
Target Recruit Count
22
Registration Number
NCT03347968
Locations
🇺🇸

Research Site, Daytona Beach, Florida, United States

D-dimer In Patients With atRial Fibrillation rEceiving antiCoagulation Therapy

First Posted Date
2017-09-12
Last Posted Date
2017-09-12
Lead Sponsor
Wuhan Asia Heart Hospital
Target Recruit Count
1194
Registration Number
NCT03280641
Locations
🇨🇳

WAHH, Wuhan, Hubei, China

Comparative Effectiveness and Safety Between Warfarin and Dabigatran

First Posted Date
2017-08-18
Last Posted Date
2019-07-09
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
22490
Registration Number
NCT03254134
Locations
🇯🇵

Nippon Boehringer Ingelheim Co., Ltd., Tokyo, Japan

Medical Need of OAC Reversal

First Posted Date
2017-08-18
Last Posted Date
2019-03-04
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
53969
Registration Number
NCT03254147
Locations
🇯🇵

Nippon Boehringer Ingelheim Co., Ltd., Tokyo, Japan

Explore the Efficacy and Safety of edoxabaN in Patients After Heart Valve Repair or Bioprosthetic vaLve Replacement (ENAVLE Trial)

First Posted Date
2017-08-09
Last Posted Date
2020-01-02
Lead Sponsor
Yonsei University
Target Recruit Count
220
Registration Number
NCT03244319
Locations
🇰🇷

Division of Cardiology, Yonsei Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of

Apixaban Versus Warfarin in Patients With Left Ventricular (LV) Thrombus

First Posted Date
2017-07-28
Last Posted Date
2021-08-25
Lead Sponsor
Hadassah Medical Organization
Target Recruit Count
40
Registration Number
NCT03232398
Locations
🇮🇱

Hadassah Medical Organization, Jerusalem, Israel

The Efficacy and Safety of Dabigatran Etexilate for the Treatment of Cerebral Venous Thrombosis

First Posted Date
2017-07-14
Last Posted Date
2017-11-22
Lead Sponsor
Capital Medical University
Target Recruit Count
80
Registration Number
NCT03217448
Locations
🇨🇳

Xuanwu Hospital Capital Medical University, Beijing, China

Comparison of Oral Anticoagulants for Extended VEnous Thromboembolism

First Posted Date
2017-06-22
Last Posted Date
2019-12-13
Lead Sponsor
Duke University
Target Recruit Count
44
Registration Number
NCT03196349
Locations
🇺🇸

University of California Irvine Medical Center, Orange, California, United States

Comparison of the Efficacy of Rivroxaban to Coumadin( Warfarin ) in Cerebral Venous Thrombosis

First Posted Date
2017-06-19
Last Posted Date
2017-06-19
Lead Sponsor
Foundation University Islamabad
Target Recruit Count
50
Registration Number
NCT03191305
© Copyright 2024. All Rights Reserved by MedPath